Skip to content

Essential Oils on Anxiety of Patients Suffering From Cancer

Impact of Essential Oils on Anxiety of Patients Suffering From Metastasis Cancer - Feasibility Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02835352
Acronym
RHECAP
Enrollment
29
Registered
2016-07-18
Start date
2016-06-21
Completion date
2017-05-01
Last updated
2018-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasm Metastasis

Keywords

anxiety

Brief summary

This study evaluates the impact of essential oils massage on anxiety of patients who are suffering from cancer at a metastasis stage. Half of patients will be massaged first by essential oils and then by oil only. The other half will be massaged first by oil and then by essential oils.

Interventions

OTHEREssential oils massages
OTHEROil massages

Sponsors

Center Eugene Marquis
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult suffering from cancer at a metastatic stage * Life expectancy \> 15 days, assessed by investigator * Hospitalized at the Chevrel unit from Centre Eugène Marquis, palliative unit care, for more than 15 days * Regular anxiolytic treatment or imperative need to introduce anxiolytic treatment (assessed by investigator) within 48 hours following his hospitalization entry * \> 18 years

Exclusion criteria

* Patient already recruited in a therapeutic trial * Patient not covered by a social security system * Pregnant or likely pregnant patient, breastfeeding patient * Allergy to any component of essential oils mixture and vegetable oils : bitter orange petitgrain, fine lavender, ylang-ylang, macadamia * Minors, people deprived of their liberty or protected people, * Impaired cognitive functions making impossible to obtain informed consent

Design outcomes

Primary

MeasureTime frameDescription
Anxiolytic consumption7 daysAnxiolytic consumption will be assessed at day 7 at the end of each phase

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026